JAK2 and myeloproliferative neoplasm: Using the highly ruxolitinib resistant JAK2-V617F + L902Q and JAK2-V617F + L983F mutations we could establish an MPN disease in mice which was similar in onset and phenotype to the original JAK2V617F model.